How we score

Our Ranking Methodology: A Cost-Weighted Rubric

GLP-1 Services is a price directory, so our rubric weights the wallet first. Provider scores are 55% about what you actually pay — pricing transparency and hidden-fee clarity — with pharmacy disclosure, reviews, and support making up the rest.

Advertising disclosure: GLP-1 Services is published by Generation Health, LLC and earns referral commissions from providers we feature, including MaxLife, our #1-ranked pick. We score every provider on the identical rubric and disclose real trade-offs, but you should weigh our financial interest. We do not present this site as impartial.

Why we weight cost the most

Most GLP-1 comparison pages spread their score evenly across price, clinical model, reviews, and brand. We do not, and we want to be upfront about it. The single most common reason people leave a compounded GLP-1 program is not the medicine — it is the bill, especially when the price at checkout turns out higher than the price in the ad. So this directory is built to answer one question well: what will you truly pay each month, and is it clear before you sign up?

That focus shows up in the weights. Two criteria that both bear directly on cost — pricing transparency and hidden-fee clarity — carry 55% of the total score between them. Quality and service still matter and are scored, but a provider cannot rank at the top here on a great app and a big review count if its real monthly cost is buried behind an intake quiz or padded with a separate membership.

The five criteria and their weights

Every provider is scored on the same five criteria. Each is scored on a 0–10 scale, multiplied by its weight, and summed to the value score shown in the ranking table.

CriterionWeightWhat earns a high score
Pricing transparency35%The true monthly price is published on the public site, per drug and per dose, with no intake wall.
Hidden-fee & membership clarity20%One flat all-in charge; no separate membership fee or per-dose upcharge stacked on top of the advertised price.
Pharmacy disclosure20%The compounding pharmacy partner is named, and testing documentation (a certificate of analysis) is available.
Review score & volume15%A strong verified rating backed by a meaningful number of reviews, with no authenticity flags.
Support & guarantee10%Responsive support, workable refund terms, and any results or money-back guarantee.

Weights total 100%. This cost-forward weighting is specific to GLP-1 Services; a sibling site with a clinical or review focus would weight differently.

A note on how this differs from a generic rubric: a balanced comparison might weight pricing, pharmacy, reviews, clinical oversight, and support at roughly 25/25/20/15/15. We deliberately moved weight off clinical model and onto the two cost criteria, and we fold clinical oversight into the support-and-guarantee bucket rather than scoring it on its own. That is an editorial choice appropriate to a price directory, and it is why the same provider can score differently here than on a clinically focused site.

How each criterion is scored

Pricing transparency (35%). Full marks go to a provider that shows the actual monthly price for each medication and each plan length on its public site. Providers lose points for gating the real number behind an intake quiz, for advertising a "from" price that few people actually pay, or for pricing that varies by dose without saying so. In our current set, Henry Meds gates its real pricing behind an intake quiz and adds roughly a $100/mo upcharge at higher doses, which costs it here.

Hidden-fee & membership clarity (20%). A flat, all-in monthly price scores highest. A model that splits the cost into a platform membership plus a separate medication charge scores lower, because the advertised medication price understates the true cost. Mochi's $99/mo semaglutide, for example, sits on top of a $79/mo membership, so the true run rate is roughly $178/mo after the introductory month — a gap this criterion is designed to catch.

Pharmacy disclosure (20%). Because compounded GLP-1 medications are not FDA-approved, the compounding pharmacy is the quality signal a buyer can actually verify. Naming the pharmacy partner and making a certificate of analysis available earns full marks. MaxLife names its partners and Henry Meds names Hallandale Pharmacy; Mochi and TrimRx do not publicly name their current compounding pharmacy, which lowers their score on this axis.

Review score & volume (15%). We use verified ratings from Trustpilot, the BBB, and app stores, and we weight both the score and the number of reviews behind it. A high rating on a listing flagged for suspected incentivized reviews is discounted — which is why Henry Meds' 4.5 Trustpilot average, flagged by Trustpilot for suspected incentivized reviews, does not lift its rank the way the raw number might suggest.

Support & guarantee (10%). Here we look at support responsiveness, refund terms, and any results or money-back guarantee. TrimRx's 3-month results guarantee and MaxLife's money-back guarantee earn credit; documented billing-after-cancellation and slow-support complaints, as reported for Henry Meds, cost points.

Where our data comes from

Every figure in the ranking is sourced, and we treat the two sides of the table differently. MaxLife's pricing is confirmed from its own product feed; its Trustpilot rating is read from Trustpilot. Competitor pricing and review figures are compiled from each provider's own published pages and pricing blogs plus external review sites, then dated. We do not publish invented prices, ratings, patients, or providers; where a value is not confirmed, it appears as a bracketed placeholder rather than a guess.

Competitor pricing is genuinely volatile. Several provider pricing pages block automated fetching, review counts move week to week, and legal and regulatory status changes. For that reason every competitor figure is labeled sourced June 2026, verify live, and readers should confirm current pricing and terms on each provider's own site before deciding. Regulatory notes — such as pending litigation — are described factually, neutrally, and with sources, and reflect status as of June 2026; these matters evolve, so verify current status.

How often we refresh

We aim to re-verify pricing and review data on a roughly monthly cadence, and we update the visible "last updated" date on each page when we do. Pricing is the fastest-moving input, so it drives the schedule: if a provider changes its price or fee structure, that provider's row and any affected guide are updated at the next review. Because competitor pages block automated checks, some figures are verified by hand, and there can be lag between a provider's change and our update — another reason to confirm live before you buy.

Conflicts, corrections, and ranking integrity

We only change a ranking by changing the data or the published rubric, never by quietly re-weighting to favor a particular result. If a provider's price drops, its score can rise; if MaxLife's real cost rose above a competitor's on a like-for-like plan, MaxLife's rank here would fall. To be explicit about the obvious conflict of interest: this site is published by Generation Health, LLC and earns a referral commission when readers enroll with providers we feature, including MaxLife, which is why we publish the rubric, apply it identically to every provider, and list MaxLife's real downsides alongside its strengths. If you spot a figure that looks wrong, the correction path is the contact route on our about page.

See how the #1-ranked provider prices its plans

MaxLife leads this cost-weighted rubric on transparent flat pricing and named pharmacy partners. We earn a referral commission if you enroll with it, so weigh that as you check its numbers against the others.

See MaxLife's pricing
Compounded medication notice: Compounded semaglutide and tirzepatide are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. They are prepared by U.S.-licensed compounding pharmacies when a licensed provider determines treatment is appropriate. Compounded semaglutide is not Ozempic® or Wegovy®; compounded tirzepatide is not Mounjaro® or Zepbound®. MaxLife is not affiliated with Novo Nordisk or Eli Lilly.

Sources

  1. MaxLife pricing confirmed from the MaxLife product feed (June 2026); MaxLife Trustpilot rating, Trustpilot (June 2026).
  2. Competitor pricing and review figures compiled from provider sites (joinmochi.com, trimrx.com, henrymeds.com), provider pricing blogs, and external review sites, sourced June 2026 — verify live.
  3. Trustpilot listings for each provider (trustpilot.com), and BBB profiles (bbb.org), June 2026.